atepeq/tico19 huggingface dataset:
about how long have these symptoms been going on?
diga ndey on ɗon mari mandolji nyau ndu?
and all chest pain should be treated this way especially with your age
e irin nawol ɓernde ndu hurgotto bana ni ɓurna be duɓɓi ma ɗo
and along with a fever
e be paaɓooje
and also needs to be checked your cholesterol blood pressure
e sey larta kolesterol ha nder ilam iyam maɗa
and are you having a fever now?
e on ɗon mari paaɓooje jonta na?
and are you having any of the following symptoms with your chest pain
e on ɗon mari mandolji nyau je ɗon limti ndu hawti be nawol ɓernde moɗon na
and are you having a runny nose?
e kine moɗon ɗon illa na?
and are you having this chest pain now?
e ɓernde moɗon ɗon nawa jonta na?
and besides do you have difficulty breathing
e fahin a ɗon mari saɗirma be fuffugo na
and can you tell me what other symptoms are you having along with this?
e footi a limta mandolji nyau feere je a ɗon mari fahin na?
and does this pain move from your chest?
e nawol man bana ɗon wanca nder ɓernde ma na?
and drink lots of fluids
e yara njaram ɗuɗum
and how high has your fever been
e deydey noy paaɓooje ma wa'i
and i have a cough too
e mi ɗon mari sondaru bo'o
and i have a little cold and a cough
e mi ɗon mari peewol be sondaru
and i'm really having some bad chest pain today
e ɓernde am ɗon nawa masiin hande
and is this the right time for your hay fever
e lati wakita ndamba ha mon timmi na
and it get the chest pain
e ɓernde bo'o ɗon nawa
and i think i have a little bit of a fever
e bana mi don mari fuɗorde paaɓooje
and i want you to describe where the chest pain is
e mi yiɗi a sappina ha toy ɓernde ma ɗon nawa
and she is sorta have the same symptoms
e o lati bana o ɗon mari irin mandolji nyau ndu.
and tell me what symptoms are you having now?
e limtinu yam mandolji nyau je on mari jonta?
and they're having some fevers as well
e be ɗon mari paaɓooje fu na
and with your history of diabetes
e be nyau sukar je on mari no
and you know it feels like my chest is like gonna crush
e on aandi bana ɓernde am fuusaan
and you know people cough on me all the time
e on aandi yimɓe ɗon sonda do am ko wetti fu
and you're having chest pain
e ɓernde mon ɗon nawa na
and your symptoms do not go away in five days
e mandolji nyau maɗa timmay ha ɓawo balde joowey.
and you said this is a pressure in your chest
e on wi'i wodi bana ɗon harla bernde mon
anyone in the family have a heart problem heart disease heart attack high cholesterol high blood pressure
wodi goɗɗo ha nder caalaje mon je ɗon mari nyau ɓernde je larni ɓesdol kolesterol ha nder ilam iyam na
any other symptoms or problems that you notice with the muscle aches?
kala mandolji nyau mala larulaji feere je on keeɓi nder ɓaandu mon?
any sharp pain on your left side of your chest?
wodi nawol feere je on ɗon naana gal jungo naano ɓernde mon na?
are there other people sick as you at home with your same symptoms?
wodi yimɓe feere je ɗon nyauɗo bana mon ha saare be irin mandolji nyau man na?
are you having any difficulty breathing now
on wodi saɗirma ngam fuffugo jonta na
are you having any other symptoms?
wodi mandolji nyau feere je on mari na?
are you having any shortness of breath?
wodi bana pofɗe moɗon timman na?
are you still having the chest pain
ɓernde moɗon ɗon nawa ha jonta na
because this is flu season
ngam lati wakati ndamba
besides the diabetes do you have other problems or important diseases?
ɓesdugo ha nyau sukar, wodi larulaji mala nyauji feere je on mari na?
but also we shouldn't be put aside for the heart cardiac origin chest pain
amma bo'o ta ɓe jo'ina amin ha seera ngam nyau ɓernde je en mari no
but a more important problem now is this chest pain
ama saɗirma je kanduɗum jonta kam lati ɓernde je ɗon nawa
but if you have the cough
ama to on ɗon mari sondaru
but i have difficulty breathing
ama mi ɗon mari saɗirma be fuffugo
but i know lot of people cough on me
ama mi aandi yimɓe jur don sonda do am
but we need to treat every chest pain with the utmost seriousness
ama sey en hurga kala ɓernde je don nawa be hakkika fu
but you're breathing all right right now right?
ama on ɗon fuffa boɗɗum jonta kam na?
cause of this chest pain i totally forgot
ngam ɓernde je ɗon nawa ndu mi ho'itti ɗum
cause they're having a cough
ngam ɓe ɗon mari sondaru
does it feel like somebody squeezing your chest
lati bana wodi goɗɗo feere ɗon i'a ɓernde mon na
do still feel like shortness of breath
ha jonta wodi bana pofɗe moɗon timman na
do they complain of being sick similar symptoms?
ɓe ɗon wi'a yo'o ɓe nyauɓe be irin mandolji nyau moɗon ndu na?
do you have any blood pressure problem as far as you know?
on ɗon mari iyam je ɗon illa be sembe je on footi mandi na?
do you have any other chronic like high blood pressure or anything like that?
on ɗon mari nyau feere je sargatta mon tum bana iyam je illata be sembe mala kuje feere bana ni na?
do you have any other diseases chronic medical problems like diabetes?
on ɗon mari nyau feere je sargatta mon tum bana nyau sukar na?
do you have any shortness of breath with that chest pain?
wodi bana pofɗe mon ɗon timma be ɓernde mon don nawa na?
do you have high blood pressure?
on ɗon mari iyam je ɗon illa be sembe na?
do you have some shortness of breath goes with that?
wodi bana pofɗe mon ɗon timma je yahidata be nyau man na?
do you know what symptoms she was having?
on aandi mandolji nyau je o ɗon no mari na?
do your relatives have the same symptoms
baabiraɓe moɗon ɗon mari irin mandolji nyau man na
do you see the image?
on ɗon lara foto ndu na?
drink plenty of fluids today
nyare njaram ɗuɗum hande
have a dry cough a cold and runny nose vomiting diarrhea
wodi sondaru je nyori, kine je ɗon feewi e je ɗon illa, ɗon tutta, be caarol
however i take tests for the diabetes
ama sey mi ngaɗa lartol nyau sukar
however she has symptoms quite similar to mine
ama o ɗon mari mandolji bana je am ndu
how high is your fever?
noy ɗaandu mon ɗon wula
how' s your blood pressure?
noy illugo iyam moɗon woni?
i don't think i have high blood pressure
mi tammay mi ɗon mari nyau illam iyam
i feel a pain in the chest here in the front part of the chest
mi ɗon maatta bana ɓernde am ɗon nawa gal yeeso ɓernde am
if you continue to have high fevers
to on ɗon tokkitira be ɓaandu mon je ɗon wula
if you have a fever of a hundred and two or higher
To ɓaandu moɗon ɓon wula bana temere e ɗiɗi mala ɓuri
if you think that your symptoms or problems warrant a better look
To on tammi yo'o on ɗon mari mandolji mala larulaji je yiɗi lartol
i got a fever yesterday
ɓaandu am ɗon no wula kenya
i got a slight fever too
mi mari no wulol ɓaandu pamarron bo'o
i had a fever yesterday
ɓaandu am wuli no seeɗa kenya
i had a short sharp pain in my chest
mi mari no nawol ɓernde caaɗungel
i have a sharp pain here in the chest
mi ɗon mari nawol ɓernde caaɗungel
i have hay fever though too
lati wakati ndamba am jonta bo'o
i have made on the body around the chest area?
mi waɗi ndu ha wakare ɓernde am fu na?
i have some difficulty breathing too
mi ɗon mari larula be fuffugo bo'o
i'll send you an image
mi neldan mon foto
i'm having some chest pain today
mi ɗon mari nawol ɓernde haande
i'm just having some headaches and some fever today
mi ɗon mari paaɓooje e be ɓaandu am don wuli seeɗa haande
in my opinion it is flu
mi tammi ɗum ndamba
in my opinion this is a little flu
mi tammi ɗum fuɗɗorde ndamba
i see it going from the center of your chest going up to your neck
mi ɗon lara yo'o ummi ha cakkare ɓernde moɗon wa'ugo gal daande moɗon
is it like some heavy heavy person sitting on your chest?
bana yimɓe je ɗon tekki jur ɗon joɗɗi do bernde moɗon na?
it all started with the headaches and with the fever about the same time
fu man fuɗɗi be paaɓooje be wulol ɓaandu ha wakati gooto
it hurts in the chest
ɗon tuffa ha nder ɓernde
it hurts in the middle of my chest
ɗon tuffa ha cakkare ɓernde
it is a pressure like chest pain
ɗum harlol bana nawol ɓernde
it is in my chest
ɓon ha nder ɗernde am
it is in the center of my chest
ɗon ha nder cakkare ɓernde am
it is in the center of the chest
ɗon ha nder cakkare ɓernde
it is occurring right in the middle of my chest
ɗon woni deydey ha nder cakkare ɗernde am
it is right in the center of my chest
ɗon deydey ha nder cakkare ɓernde am
it sounds like you just may have the garden variety cold or a flu
lati bana on ɗon mari ndamba dummol feere-feere tan
i've got pain in my chest
mi keɓɓi no nawol ha nder ɓernde am
i've very concerned of this chest pain
nawne ɓernde ndu ɗon sakla mi masitin
i want you to tell me in describing this chest pain
mi yiɗi on ngewtina mi do noy ɓernde ndu ɗon nawa
i will send you an image
mi neldan mon foto
i will send you an image on your screen
mi yarɓan foto ha do ordo mon
like high blood pressure or diabetes
bana nyau illam iyam mala nyau sukar
like right in the center of the chest
bana deydey ha nder cakkare ɓernde
most of the time it is this type of chest pain
burna fu lati irin nawol ɓernde ndu
my sister has similar symptoms
deerɗiko am debbo ɗon mari irin mandolji nyau ndu
now for the fever you can take a tachipirina sweet
jonta kam footi a hocca tachipirina ngam wulol ɓaandu ndu
now i send you an image
mi ɗon yarɓa foto jonta
now mary how many days have you had the symptoms
jonta kam Mary diga balɗe noy a don mari mandolji nyau ndu
now you said you have a chest pain
jonta a wi'i a don mari nawol ɓernde
occasionally i have some chest pain
ndego-ndego mi ɓon mari nawol ɓernde
okay are you having any other symptoms along with this other than just the pain
too, on ɗon mari mandolji nyau feere je yahidatta be man ha ɗawo nawol ndu na
or if you have high blood pressure
mala to a ɗon mari iyam je ɗon illa be sembe
or somebody sitting on your chest?
mala goɗɗo ɗon joɗɗi do ɗernde mon?
pretty much the same with the fever and the cough headache and muscle pains
lati bana ni be wulol ɓaandu be sondaru, paaɓooje be nawne ɓaandu
right in the middle of my chest
deydey ha cakkere ɓernde am
show me on this image where you feel the pain
sappinam ha do foto ndu ha toy ɓernde ma ɗon nawa
since you have a fever
diga ɓaandu mon ɗon wula
so do you think that some of these symptoms could be related to being pregnant?
ni kam on tammi yo'o mandolji nyau ndu footi wanga to goɗɗo ɗon be reedu na?
so your chest pain started this morning
ni kam nawnol ɓernde ma fuɗɗi hande be fajiri
so your children are having some of the same symptoms?
ni kam ɓikkon mon ɗon mari feere'en ha cakka irin mandolji nyau ndu na?
tell me about your chest pain
ngewtinam do bernde mon je ɗon nawa
the fever increases at night
ɓaandu man ɓesdi wulugo be jemma
the fever i've had for the last two days
ɓaandu am fuɗɗi wullugo do diga balɗe ɗiɗi je sallingo
the fever started to increase last night
ɓaandu am besdi wullugo kenya be jemma
the fever started two days ago
ɓaandu am fuɗɗi wullugo diga balɗe ɗiɗi
the muscle pains with the hay fever
nawol ɓaandu be ndamba wakati
this is doctor porter in the emergency room triage center
nda lekkitajo je suklata do ɗowirde suudu jaawal
well can you tell me a little bit more about your chest pain?
too, footi on ngewtina mi fahin do nawol ɓernde ma go na?
well from my point of view it is a little flu
too, ha min kam ɗum fuɗɗorde ndamba tan
well i feel a pain in the front of my body here in my chest
too, mi ɗon maata nawol gal yeeso ɓaandu am ha nder ɓernde
well i've been having a strong pain in my chest
too, ɓernde am ɗon no nawa ɓuri am sembe
well madam from listening to your symptoms it sounds like you've got one of the flu viruses
too, debbo, ha nder ko mi heɗɗitti nder mandolji nyau ma ndu bana on raɓɓi gilɗi ndamba
well when i have that pain in my chest
too, to mi ɗon mari nawol ndu ha nder ɓernde
what kinda pain do you have in your chest?
irin nawol toy on ɗon mari ha nder ɓernde mon?
when this chest pain started?
ndey nawol ɓernde man fuɗɗi?
where do you have the pain in the chest?
ha deydey toy ɓernde mon ɗon nawa?
you are probably having chest pain
temma a ɗon mari nawol ɓernde
you feel like tightness on your chest
lati bana ɓernde mon ɗon saati
you know i got diabetes and stuff
on aandi mi ɗon no mari nyau sukar be feere
you said you're having this chest pain
on wi'i on ɗon mari nawol bernde ndu
Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020
Nyau koronaviriis je ɗon dogga e ɗon fittina ndu (COVID-19) ha Kawtirol lesɗe Erop/Wakere Sigorde Erop be Kawtal lesɗe Inglisiya, 1 Zaanviye ha 15 Maars 2020
The cumulative incidence of coronavirus disease (COVID-19) cases is showing similar trends in European Union/European Economic Area countries and the United Kingdom confirming that, while at a different stage depending on the country, the COVID-19 pandemic is progressing rapidly in all countries.
Nyauɓe nyau koroonaviriis je ɗon hawti ndu (COVID-19) ɗon sappina yaɓordeji kalkal bana ha Kawtirol lesɗe Erop/Sigorde lesɗe Erop be Kawtal lesɗe Inglisiya je ɗon aanɗina ɗum, nden bo'o ha yakke feere, nyau COVID-19 ɗon doggina be jaawal ha nder lesɗe duniyaru fu.
Based on the experience from Italy, countries, hospitals and intensive care units should increase their preparedness for a surge of patients with COVID-19 who will require healthcare, and in particular intensive care.
To en joɗɗi ɗo ko salli ha Italy, leesɗe, cuuɗi lekki be geeɓe sukloɓe do nyauɓe sey ɓesda taskaram maɓɓe ngam limgal nyauɓe COVID-19 je emman suklare do ɓaandu maɓɓe, be suklare je feerejo ɓesdan.
On 31 December 2019, a cluster of pneumonia cases of unknown aetiology was reported in Wuhan, Hubei Province, China.
Ha 31 Desambre 2019, wodi kawtal gilɗi ɓernde feere je inde man aandaka wangi ha Wuhan, Lamorde Hubei, Cayna.
On 9 January 2020, the China Center for Disease Control and Prevention reported the causative agent as being a novel coronavirus now referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
ha 9 Zaanviye 2020, Geeɓe Aynol be Lartol Nyau Lesdi Cayna wi'i yo'o ko je umminata koronaviriis je keese ndu je ewnotto haande bana nyau pofɗe je koronaviriis 2 (SARS-CoV-2).
Since, the illness resulting from SARS-CoV-2 infection has been named coronavirus disease (COVID-19).
Diga nden, nyau je wangi gal SARS-CoV mbiyotto nyau (COVI-19).
Evidence to date is that ca 80% of individuals with COVID-19 have a mild disease, i.e. a respiratory tract infection with or without pneumonia, and most of these recover.
Sappinolji haande wi'i yo'o deydey yimbe 80% ɗon mari nyau je nyaɗay masin, bana wi'ugo yo'o nyau je raɓɓatta lawol pofɓe, e burna fu ɗon nyambitta.
In ca 14% cases, COVID-19 develops into a more severe disease requiring hospitalisation while the remaining 6% cases experience critical illness requiring intensive care.
Ha nder 14% nyau, COVID-19 ɗon lata nyau je ɗon nyaɗi e emmotto jonde ha nder suudu lekki e 6% nyauɓe do nyaara bone e sey lekkitaɓe sukla masitin do maɓɓe.
The mortality of patients hospitalised due to COVID-19 is ca 4%.
Mayde nyauɓe je wondi ha suudu lekki ngam COVI-19 waɗan 4%.
In this study, we assess the trends in the cumulative incidence of COVID-19 in each European Union/European Economic Area (EU/EEA) country and the United Kingdom (UK) and compare them to that of Hubei Province, China.
Ha nder ekkitol ndu, min ɗon larta yahde kawtal nyau COVID-19 je ɗon fitina ha kala lesdi Kawtirde Erop/Sigorde Lesde Erop (EU/EEA) be Kawtal lesee Inglisiya (UK) e larta ɗum je woni ha Lamorde Hubei, Cayna.
We also compare the current number of COVID-19 cases in EU/EEA countries and the UK with that in Italy during 31 January–15 March 2020.
Mi ɗon fonda bo'o limgal nyauɓe COVID-19 je jonta ha lesɗe EU/EEA be UK be ɓe'en je wondi ha Italy 31 Zaanviye ha 15 Maars 2020.
COVID-19 cases in EU/EEA countries and the UK
Nyauɓe COVID-19 ha lesɗe EU/EEA be UK
Subsequent to China, COVID-19 underwent further geographical spread and the dynamic of the COVID-19 pandemic in the rest of the world currently follows that of this country.
Ha ɓawo Cayna, COVID-19 hoosi wakereji feere e yahde nyau COVID-19 ha luttuɗum nukkure lesɗe ha nder duniyaru jonta ɗon tokka je lesdi ndu.
On 11 March 2020, the Director General of the World Health Organization (WHO) declared COVID-19 a pandemic.
Ha 11 Maars 2020, Arandere Ɗowuwo Ɗowirɗe Jam Ɓaandu Duniyaru (WHO) matini yo'o COVID-19 lati nyau duniyaru fu.
In the 5 March issue of Eurosurveillance 2020, Spiteri et al. reported on the first European confirmed COVID-19 cases according to the WHO case definition.
Ha wurtol Eurosurveillance je 5 Maars 2020, Spiteri al. matini do arandere nyauɓe COVID-19 je gonga ha Erop bana ko WHO mbiy.
In the EU/EEA, the first three confirmed cases were reported by France on 24 January 2020 in persons returning from Wuhan, Hubei Province, China.
Ha EU/EEA, arandere nyauɓe je tati je Faransa matini ha 24 Zaanviye 2020 ha lornooɓe berniwol Wuhan, Lamorde Hubei, Cayna.
As at 15 March 2020, COVID-19 cases had been detected in all 30 EU/EEA countries and the United Kingdom (UK), whereby between 31 December 2019 and that date included, 39,768 cases and 1,727 deaths had been reported, with 17,750 cases and 1,441 deaths from Italy alone.
Ha 15 Maars 2020, nyauɓe COVID-19 tawama ha 30 lesɓe EU/EEA e ha Kawtal lesɗe Inglisiya, je ha kunde 31 Desambre 2019 e ha wakati ndu be tawi nyauɓe 39 768 be mayɓe 1 727 e bo'o be mayɓe 1 441 ha lesdi Italy feere mum.
Obtaining cumulative number and cumulative incidence of COVID-19 cases
Keeɓɓugo kawtal limgal be kawtal nyauɓe COVID-19
At the European Centre for Disease Prevention and Control (ECDC), the notified COVID-19 case counts in each country worldwide, obtained from only official sources such as the countries’ Ministry of Health, national and regional health authorities and the WHO, are updated each day at 8:00 a.m.
Ha Geeɓe Aynol be Lartol Nyau ha Erop (ECDC), limgal nyauɓe COVID-19 ha kala lesdi fu ha nder duniyaru, je ɗon mofti ha yimɓe je ɗon mari amana bana Arduɓe Geeɓe Jam Ɓandu, jagorɓe lesdi nder be je berniwol be WHO latan lartama ko wetti fu be njamdi 8:00 asiri.
These data were used for assessing the trends of COVID-19 in EU/EEA and the UK, and comparing them to that in Italy.
Matinolji ndu je be huwidi be mum ngam lartol COVID-19 ha EU/EEA e ha UK, e foondugo ngu be je Italy.
As a proxy of the prevalence of active COVID-19 cases, we calculated the 14-day truncated cumulative incidence of COVID-19 cases, thus taking into account the natural course of COVID-19, in each EU/EEA country and the UK, during the 1 January–15 March 2020 period.
Bana lartol limgal nyaube je mari COVI-19, en limmi hawtirde larulaji lanyoɓe COVID-19, ndego en limmi yahde COVID-19 ha kala lesdi je EU/EEA be lesdi UK diga nyalade 1 lewru Zaanviye ha nyalade 15 lewru Maars 2020.
We also presented the cumulative number of notified cases of each country as at 15 March 2020 8:00 a.m. compared with that of Italy for the 31 January–15 March 2020 period.
En sappini bo'o kawtal limgal nyauɓe je matinama ha kala lesdi ha 15 Maars 2020 be njamdi 8:00 fajiri ɗo je larni lesdi Italy diga wakati 31 Zaanviye ha 15 Maars 2020.
Trends of COVID-19 in EU/EEA countries and the UK
Yahdeji COVID-19 ha lesɗe EU/EEA be UK.
The trends in the 14-day truncated cumulative incidence of COVID-19 cases in EU/EEA countries and the UK generally followed that of Hubei Province (China) (Figure 1).
Yahdeji ha nder ta'irde kawtal limgal nyauɓe COVID-19 ha lesɗe EU/EEA nder balɗe 14 be UK tokkiti ɓurna fu je Lamorde Hubei (Cayna) (Foto 1).
For the EU/EEA and the UK overall, the cumulative incidence of COVID-19 started to increase around 21 February and then increased sharply around 28 February 2020 (Supplementary material).
Ko larni EU/EEA be UK fu, kawtal limgal nyauɓe COVID-19 fuɓɓi ɓesdugo gal 21 Feviriye e faawi gal 28 Feviriye 2020 (Kujeji feere).
This was mostly driven by the rapid increase in the number of reported cases from Italy, but all other EU/EEA countries and the UK showed similar increasing trends of the cumulative incidence of COVID-19 (Supplementary material).
Ɓurna ko wartiri ndu bani ɗo ɗum wa'ugo limgal nyauɓe je matinama ha lesdi Italy, ama luttuɗum lesɗe EU/EEA fu be UK sappini irin yahdeji kawtal limgal COVID-19 (Kujeji feere).
Figure 2 shows the cumulative number of COVID-19 cases, in EU/EEA countries and the UK compared with that in Italy for the 31 January–15 March 2020 period.
Foto 2 don sappina kawtal limgal nyaube COVID-19, ha lesɗe EU/EEA be UK to fondi be je Italy ha wakkati 31 Zaanviye ha 15 Maars 2020.
It highlights that, as at 15 March 8:00 a.m., 15 other EU/EEA countries and the UK had already reported a total number of cases comparable to that of Italy just 3 weeks prior or less.
Don sappina yo'o, ha 15 Maars be njamdi 8:00 fajiri, 15 lesɗe EU/EEA be UK feere matini limgal nyauɓe je footi fonda be je Italy ha nder balɓe 3 hideko mala ha ɓawo timmi.
Our results indicate that the number of notified cases of COVID-19 is rapidly increasing in the EU/EEA and the UK.
Ko waangi don sappina yo'o limgal nyauɓe COVID-19 je matinama don wa'a be sembe EU/EEA be UK.
The observed trends in the cumulative incidence of COVID-19 suggest that the pandemic is progressing at a comparable speed in all countries.
Yaɓorde je en ɗon lara be yahidugo COVID-19 ɗon sappina nyau ɗon yahida be sappinol je foooti larta ha nder lesɗe fu.
This is despite countries being at different stages, variations in national public health responses, and possibly different case definitions in countries and different protocols for selecting patients that must be tested for confirmation of COVID-19, including catch-up testing.
Ndu ngam lesɗe wondi ha yahde feerejo, saanjolji ha jaɓɓuji mo je suklatta do jam ɓaandu lesdi, be sappinol nyau feere-feere ha lesɗe be dabareji feere ngam suɓɓol nyauɓe je sey larta ɓaandu maɓɓe fahin ngam COVID-19, be lartol fahin.
Early March 2020, doctors in the affected regions of Italy described a situation in which ca 10% of patients with COVID-19 required intensive care and media sources reported that hospitals and intensive care units in these regions had already reached their maximum capacity.
Ha fuɗorde Maars 2020, lekkitaɓe ha nder wakkereji Itali je ɗon raɓɓi timmi sappini kuje feere je 10% cakka nyauɓe COVID-19 mari no haaje suklare maungel e hubaruuji mbiy yo'o cuuɗi lekki be geeɓe sukloɓe do nyauɓe ha nder wakereji ndu jokki hebbinol maɗa.
Data on admission of COVID-19 cases in a hospital and/or an intensive care unit are currently available at EU/EEA level for only 6% and 1% cases, respectively (data not shown).
Matinolji do nyauɓe COVID-19 ha nder suudu lekki e/mala geeɓe suukloɓe do nyauɓe ɗon woni ha deydey EU/EEA je nyauɓe 6% be 1%, feere-feere (be sappinay matinolji).
They should, however, be collected in a systematic fashion to complement current surveillance data that focus on the number of reported cases and the number of deaths.
Sey, bo'o, ɓe hawta ndu fu ha baabe gooto ngam cikkugo matinolji aynol je ɗon larna limgal nyauɓe je don aandin be limtol mayɓe.
A study performed in 2010–11 showed a large variation in the availability of intensive care and intermediate care beds in Europe, ranging from 29.2 in Germany to 4.2 beds per 100,000 population in Portugal.
Ekkitol feere ha 2010-2011 sappini saanjol maungel je woni ha nder wondugo leesoje be ordoji je suklugo do nyauɓe je ɓuri nyaɗugo be je deydey ha Erop, fuɗɗam diga leesoje 29.2 ha lesdi Jamani ha 4.2 ngam yimɓe 100 000 ha Portugal.
This means that countries may have more or less resources than Italy (12.5 intensive care and intermediate care beds per 100,000 population in 2010–11).
Bana wi'ugo lesɗe ndi footi wonda be disku ɗuri mala famɗi do Italy (12.5 leeso suklare ɗuɗum be suklare deydey ngam ummatore 100 000 ha 2010-11).
Modelling scenarios related to healthcare capacity saturation, with estimates for each EU/EEA country and the UK of the prevalence of hospitalised COVID-19 cases associated with a &gt; 90% risk of exceeding intensive care bed capacity, are provided in the sixth update of the ECDC rapid risk assessment on COVID-19.
Taskugo jaahargalji je larni dabare jaɓɓitugo, be ko footi kala lesɗe EU/EEA be UK jaɓɓa nyauɓe COVID-19 je ɗon mari haaje yahugo ha suudu lekki e je ɗon mari bo'o haaje leesoje je ngiɗi sey mara ordoji je suklugo do goɗɗo ha pettum man 90% ha nder jooweyaɓre ɗerewol lartol ECDC do lartol nyaugo ngam COVID-19.
Since cases have so far clustered in certain regions in EU/EEA countries and the UK, and hospitals and intensive care units usually serve a defined regional catchment population, information about cases and intensive care beds should preferably be made available at the Nomenclature of territorial units for statistics 2 (NUTS-2) level.
Ngam nyauɓe ɓesdi e mofti ha nder wakereji lesɗe EU/EEA be UK feere, be cuuɗi lekki be geeɓeji sukloɓe do nyauɓe ɗon huwida ha wakere je don nyukki ha nyimɓe, matinolji do nyauɓe be leesoji je ɗon mari ordoji footi wonda ha kala Marde berniwolji fu ngam haala laasafi 2 (NUTS-2).
The experience from Italy and the current trends in other countries show that the COVID-19 pandemic is progressing rapidly in the EU/EEA and the UK.
Ko salli ha Italy e hahde je jonta ha lesɗe feere ɗon sappina nyau COVID-19 ɗon dogga law ha lesɗe EU/EEA be UK.
Countries, hospitals and intensive care units should thus prepare themselves for a scenario of sustained community transmission of SARS-CoV-2 and an increase in the number of patients with COVID-19 requiring healthcare, and in particular intensive care, such as the one occurring in the affected regions of Italy.
Lesɗe, cuuɗi lekki be geeɓe sukloɓe do nyauɓe sey taska hoore maɓɓe do dabare wallugo ummatore ngam naangugo SARS-CoV-2 e ɓesdare nder limgal nyauɓe je ɗon mari COVID-19 je mari haaje jam ɓaandu, be suklare je feerejo, bana je don salla ha wakereji raɓɓungel Italy.
As pointed out in the recent ECDC rapid risk assessment, a rapid, proactive and comprehensive approach is essential to delay the spread of SARS-COV-2, with a shift from a containment to a mitigation approach, as the anticipated rapid increase in the number of cases may not provide decision makers and hospitals enough time to comprehend, accept and adapt their response accordingly if not implemented ahead of time.
Bana ɗon limti ha nder lartol raɓɓol laugel ECDC, wodi dabare je ɗon timmi e je yahidatta be haɗol yajjugo SARS-COV-2, be dabare je yahatta diga hurgol ha ustol, bana limgal nyauɓe je ɗon no ɓesda footay hokka wakati deydey ha hoosoɓe hasduji ngam fammugo, jabbugo e haɓda dabare jabbuye maɓɓe to hasday be wakati.
The rapid risk assessment also lists the public health measures to mitigate the impact of the pandemic.
Lartol raɓɓol je laugel ngu ɗon limta bo'o dabareji jam ɓaandu ngomna ngam ustugo sembe nyau duniyaru ndu.
There is a short window of opportunity during which countries have the possibility to further increase their control efforts to slow down the spread of SARS-CoV-2 and decrease the pressure on healthcare.
Wodi tammunde dabare je footi walla lesɗe nder heɓɓugo dabareji besdugo sembe maɓɓe nder ustugo yajjol SARS-CoV-2 be ustol jaawal ha do suklare do jam ɓaandu.
Failing this, it is likely that the healthcare systems of other EU/EEA countries will face a surge of patients that require intensive care within the coming days or weeks.
To sallay bana ni, lati bana dabare suklugo do jam ɓaandu lesɓe EU/EEA feere heɓɓan larula ngam limgal nyauɓe je mari haaje suklare je feerejo ɓesdan ha nder balɗe mala asaweji je warango.
The outbreak of Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has thus far killed over 3,000 people and infected over 80,000 in China and elsewhere in the world, resulting in catastrophe for humans.
Nyau koronaviriis 2019 (COVID-19), je ɗon wangi gal gilɗi larula nder fuffugo (SARS) koronaviriis 2 (SARS-CoV-2), mbari kadi ɓuran yimɓe 3 000 e raɓɓi ɓuri 80 000 ha Cayna e ha nukkure lesdi feere ha nder duniyaru, je lati bana wahala ha yimɓe.
Similar to its homologous virus, SARS-CoV, which caused SARS in thousands of people in 2003, SARS-CoV-2 might also be transmitted from the bats and causes similar symptoms through a similar mechanism.
Bana naandu mako, SARS-CoV, je ummini SARS ha ujeneje yimɓe ha 2003, SARS-CoV-2 footi salla diga bilwili e hokka irin mandolji nyau ndu gal irin lawol man.
However, COVID-19 has lower severity and mortality than SARS but is much more transmissive and affects more elderly individuals than youth and more men than women.
Ama, COVID-19 lessi mbarugo e nyaɗugo do SARS ama ɓuri raɓɓugo e ɓurna fu ɗon rabba ndotti'en do sukkaɓe e ɓurna worɓe do rewɓe.
In response to the rapidly increasing number of publications on the emerging disease, this article attempts to provide a timely and comprehensive review of the swiftly developing research subject.
Ngam jaɓɓugo do limgal nyauɓe je ɗon ɓesda law do nyau je ummi nga, batakewol ndu ɗon haɓda be hokkugo lartol be wakati e be gongaku do ko don larti ha nder teffol ndu.
We will cover the basics about the epidemiology, etiology, virology, diagnosis, treatment, prognosis, and prevention of the disease.
Min lartan bo'o do ekkitol do raɓɓol nyau, daaɗol nyau ndu, ekkitol do viriis man, lartol, hurgol, tammunde, be aynol nyau ndu.
Although many questions still require answers, we hope that this review helps in the understanding and eradication of the threatening disease.
Ko to emmolji ɗuɗum kebbay jabbuji, min tammi yo'o batakewol ndu don walla ha nder fammugo e willugo nyau ndu.
The Spring Festival on January 25, 2020 has become an unprecedented and unforgettable memory to all Chinese who were urged to stay indoors for all the holiday and for many weeks after due to the outbreak of a novel viral disease.
Spring Festival ha 25 Zaanviye 2020 lati bana ko meeɗay e yejjitatakke ha ummatore Cayna fu je be dolli be wondugo ha saare ha nder wakati siwtare fu e asaweji ha bawo man ngam nyau viriis keese waangi.
The virus is highly homologous to the coronavirus (CoV) that caused an outbreak of severe acute respiratory syndrome (SARS) in 2003; thus, it was named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020, and the associated disease was named CoV Disease-19 (COVID-19).
Viriis man ɗon nandi koronaviriis (CoV) je ummini nyau ɓernde je nyaɗungel (SARS) ha 2003; ngam man kadi Geeɓe Jam Ɓaandu ha Duniyaru ewni dum SARS-CoV-2, e nyau man ewnotto Nyau CoV 19 (COVID-19).
The epidemic started in Wuhan, China, and quickly spread throughout the entire country and to near 50 others all over the world.
Nyau man fuɗɗi ha Wuhan, Cayna, e ɓawo man raɓɓi lesdi man fu nden bo'o ɓadi lesde 50 ha nder duniyaru.
As of March 2, 2020, the virus has resulted in over 80,000 confirmed cases of COVID-19, with more than 40,000 patients discharged and over 3,000 patients who died.
Diga 2 Maars 2020, viriis man raɓɓi yimɓe 80 000 je aandin mari COVID-19, be nyauɓe 40 000 je ɗon hurgi be nyauɓe ɓuri 3 000 maynama timmi.
WHO warns that COVID-19 is “public enemy number 1” and potentially more powerful than terrorism.
WHO ɗon matina yo'o COVID-19 lati "aranol gaynyo yimɓe" e footi ɓura hulturol.
According to PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), in less than two months, over 200 papers have been published on COVID-19 including its virology, epidemiology, etiology, diagnosis, and treatment since the first report on January 7, 2020 that determined the sequence of the virus isolated from multiple patients.
Ko bana don sappini ha PubMed (https://www.ncbi.nlm.nih.gov/pubmed), hideko leebi ɗiɗi, ɓuri ɗereji 200 ngurti do COVID-19 be aandal do gilɗi ndu, turtol, lartol, e hurgol diga aranol batakewol ha 7 Zaanviye 2020 je sappini gilɗi ndu je ɗon feeretiri ha nyauɓe ɗuɗum.
This review attempts to summarize the research progress in the new and swiftly developing subject area.
Lartol ndu ɗon fonda wurtinugo cakkare yahde teffol ha nder ekkitol keese e be jaawal bo'o
Whenever possible, we will try to compare COVID-19 with SARS and another CoV-caused disease, Middle East respiratory syndrome (MERS, an outbreak in 2012).
Bana ko wowa, min fondan lartugol COVID-19 be SARS be nyau feere, mbiyotto Nyau Pofɗe Cakkare Funaange (MERS, nyau feere ha 2012).
We will also discuss what we have learned so far regarding the prevention and prognosis of the disease as well as some remaining yet urgent questions.
Min tamman bo'o ngewtugo do ko en ekkiti ko larni aynol e tammunde do nyau be emmolji je lati bana jaawal ha jonta.
CoVs have been traditionally considered nonlethal pathogens to humans, mainly causing approximately 15% of common colds 4.
CoV ji lati no bana gilgiji je footay mbara neɗɗo no aran, je ɗon ummina ndamba ha 15% cakka ndambaji 4.
However, in this century, we have encountered highly pathogenic human CoVs twice, i.e., SARS-CoV and MERS-CoV, which caused an outbreak originally in China in 2003 and Saudi Arabia in 2012, respectively, and soon spread to many other countries with horrible morbidity and mortality.
Amma, ha nder ujenere ndu, min footi be CoV ji ɗon nyaɗi nangugo neɗɗo nde ɗiɗi, bana wi'ugo, SARS-CoV be MERS-CoV, je arti be nyau feere ha lesdi Cayna ha 2003 be Arabiya ha 2012, e ha ɓawo man yotti ha lesɗe feere be limtol e limgal wade je don hultora.
Therefore, the current COVID-19 is the third CoV outbreak in the recorded history of humans.
Nden bo'o, COVID-19 je jonta ndu lati nyau CoV je tataɓre ha nder tariya neɗɗo.
As shown in Fig. ​Fig.1,1, clusters of pneumonia that had unknown origins were first reported from Wuhan on December 31, 2019 to the China National Health Commission.
Bana ɗon sappini ha do Foto, Foto 1,1, samere nyau ɓernde je goɗɗo aanda daaɗi man ummiki ha Wuhan tawon ha 31 Desambre 2019 ha Geeɓe Jam Ɓaandu Lesdi Cayna.
Seven days later the sequence of the CoV was released.
Ha ɓawo ɓalde joowey e ɗiɗi ta'irde CoV wurti.
On January 15, 2020 the first fatal case from Wuhan was reported.
Ha 15 Zaanviye 2020 aranol nyauɗo mayi ha Wuhan.
Meanwhile, the epidemic rapidly spread to the neighboring cities, provinces, and countries.
Ha wakati nde, nyau man fuɗɗi yajjugo ha berniji, lamordeji, be lesɗe feere.
On January 20, the infection of health-care providers was reported, suggesting that human-to-human transmission was possible.
Ha 20 Zaanviye, be matini nyau sukloɓe do nyauɓe, je sappinatta no yo'o footi nyau man salla diga neɗɗo ha neɗɗo.
On January 23, the city of Wuhan was locked down with all its public transportation stopped.
Ha 23 Zaanviye 2020, berniwol Wuhan maɓɓakke be jaahangalji fu darnama.
On January 24 the first clinical study on the disease reported that, out of 41 patients with confirmed cases, only 21 had direct contact with the Wuhan seafood market that was considered the starting site of the infection from an unknown animal source.
Ha 24 Zaanviye aranol ekkitol do nyau je be larti ha suudu teffol wi'i yo'o, ha cakka nyauɓe 41 je ɗon mari nyau man timmi, sna 21 footi be lumo dabaji je Wuhan, je hoccama bana baabal fuɗorde nyau je wurti ha daaba feere je aandakke.
On January 30, WHO declared the outbreak a global health emergency.
Ha ɓawo 30 Zaanviye, WHO matini jaawal jam ɓaandu ha nder duniyaru.
By the time of this report, the disease has already spread throughout China and near 50 other countries all over the world (Fig. ​(Fig.2).2).
Ha wakati windol batakewol ndu, nyau ndu yajji timmi ha lesdi Cayna e ɓadi lesɗe 50 ha nder duniyaru fu (Foto (Foto 2).).
As the situation is rapidly evolving, the final scope and severity of the outbreak remain to be determined.
Ko bana nyau man ɗon yahda law, ragare tammunde e nyaɗol nyau mala mo footi famma tawon.
On February 11, 2020, a multi-center study on 8,866 patients including 4,021 confirmed COVID-19 patients presented a more updated illustration of the epidemic as follows (https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA).
Ha 11 Feviriye 2020, wodi ekkitol do nyauɓe 8 866 be nyauɓe je ɗon mari nyau COVID-19 timmi 4 021 ha suudu lartol feere-feere sappini sappinol keese do nyau ndu bana ni (https://mp.weixin.qq.com/s/UIBi-HX_rHPXa1qHA2bhdA).
SARS-CoV-2 infected people of all ages, but mainly at the age of 30-65.
SARS-CoV-2 rabbi yimɓe duɓɓi fu, ama ɓurna be'en je mari 30 ha 65.
Almost half (47.7%) of the infected individuals were over 50 years old, very few were under 20, and only 14 infected individuals were under the age of 10.
Ɓurna reeta (47.7%) yimɓe je nangi nyau ndu ɓuri duɓɓi 50, ɓe'en je maray duɓɓi 20 woonay jur, e sna yimɓe 14 je ɗon mari nyau man je yottay duɓɓi 10.
SARS-CoV-2 infected more men (0.31/100,000) than women (0.27/100,000).
SARS-CoV-2 raɓɓi ɓurna worɓe (0.31/100,000) do rewɓe (0.27/100,000).
COVID-19 expanded in clusters mainly in and around Hubei.
COVID-19 yajji nder sammere be geebeji burna ha Hubei e ha tarde man.
COVID-19 took an average of 5 (2-9) days from onset to diagnosis.
COVID-19 hoosi no deydey balɗe 5 (2 ha 9) diga fuɗɗam ha lartol.
The average incubation period was 4.8 (3.0-7.2) days.
Wakati deydey wangugo lati no balɗe 4.8 (3.0 ha 7.2)
The average time from onset to death was 9.5 (4.8-13) days.
Wakati je deydey diga fuɗɗam ha waade lati no balɗe 9.5 (4.8 ha 13).
The basic reproductive number (R0) was 3.77 (95% CI: 3.51-4.05), and the adjusted R0 was 2.23-4.82.
Aranol lamba dayinki (R0) ɗon no 3.77 (95% CI:3.51-4.05), be R0 je lartama ɗon no 2.23-4.82.
The number of infected people increased exponentially before 23 Jan. 2020, matching the time of massive transportation before the Spring Festival in China.
Limgal nyauɓe do wa'a ɓuri sembe hideko 23 Zaanviye 2020, je ɗon hawta wakati yortol jaahangal hideko Spring Festival ha Cayna.
The mortality of patients with confirmed cases was 1.44% (95% CI: 1.10-1.86%), and the adjusted mortality of all the patients was 3.06% (95% CI: 2.02-4.59%).
Mayde nyauɓe je ɗon aandi mari nyau man ɗon no 1.44% 59% CI:1.10-1.86%), be limtol mayde je nyauɓe fu lartamma ɗon no 3.06% (95% CI: 2.02-4.59%).
Three major risk factors for COVID-19 were sex (male), age (≥60), and severe pneumonia.
Wodi kujeji tati je ɗon ɓuri umminugo nyau COVID-19 ɗon no baadal (gorkol), duɓɓi (≥60), be nyau ɓernde je nyaɗi masitin.
CoVs are a subfamily of large and enveloped viruses containing a single strand of sense RNA.
CoV ji lati bana geeɓe caalage e viriis je ɗon suɗɗi je ɗon mari kosɗe RNA gooto.
They can be divided into four genera, i.e., alpha, beta, gamma, and delta, of which alpha- and beta-CoVs are known to infect humans.
Footi senda be nde geeɓe nay, bana wi'ugo, alpha, beta, gamma, delta, e cov alpha be beta lati bana ɗon raɓɓa neɗɗo.
The envelope spike (S) glycoprotein binds to its cellular receptors angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) for SARS-CoV and MERS-CoV, respectively, and then membrane fusion occurs.
Ɓawo laaral (S) glycoprotein ɗon takka be bawo man je ɗon jaɓɓitta angiotensin e ɗon lorna neebam 2 (ACE2) be dipeptidyl peptidase 4 (DPP4) ngam SARS-CoV be MERS-CoV, feere-feere, nden kadi hawtirde ngaɗa.
The viral RNA genome is released into the cytoplasm; after replication of the viral genome, genomic RNA accompanied by envelope glycoproteins and nucleocapsid proteins forms virion-containing vesicles, which then fuse with the plasma membrane to release the virus.
Genome RNA viriis yoffama ha nder cytoplasme; ha ɓawo danyinki genome, RNA genome be laaral protein glycoproteinji be nucleocapsid ɗon ngada cuuɗi pamarron je jaɓɓitatta ɓiɓe viriis, je nastan e hawtan be neebam iyam e yooffa viriis.
The first genomic sequence of SARS-CoV-2 was reported on January 10, 2020.
Aranol ta'irde SARS-CoV-2 matinama ha 10 Zaanviye 2020.
SARS-CoV-2 was found to be a new type of beta-CoV with more than 99.98% genetic identity among 10 sequenced samples collected from the original site of the outbreak, the Huanan Seafood Market in Wuhan.
SARS-CoV-2 tawama bana beta-CoV keese ɓuri naandu tagɗe 99.98% ha kunde ta'irdeji 10 je be hoosi ha aranol wakere je nyau man fuɗɗi ha ton, Huanan Seafood Market ha Wuhan.
SARS-CoV-2 is genetically more similar to SARS-CoV than to MERS-CoV.
SARS-CoV-2 ɗon nandi gal tagol mako be SARS-CoV do MERS-CoV.
Through transmission electron microscopy, SARS-CoV-2 particles were found in ultrathin sections of human airway epithelium.
Gal sappinol electron je pamarron, coolaaje SARS-CoV-2 tawamam ha nder ta'irdeji ultrethin je epithelium lawol pofɗe neɗɗo.
Human ACE2 was found to be a receptor for SARS-CoV-2 as well as SARS-CoV.
ACE2 neɗɗo tawama bana latotto jabbowo SARS-CoV-2 bana SARS-CoV.
However, the S protein of SARS-CoV-2 binds to human ACE2 more weakly than that of SARS-CoV, which is coincident with the fact that SARS-CoV-2 causes less severe infection in patients than SARS-CoV.
Ama, protein S je SARS-CoV-2 ɗon takka be ACE2 neɗɗo ɓuri dayugo do SARS-CoV? je hawti be je SARS-CoV-2 je nyau man nyaɗay masin do SARS-CoV.
SARS-CoV-2 can also form a novel short protein encoded by orf3b and a secreted protein encoded by orf8.
SARS-CoV-2 footi bo'o tagga protein pamarron be lamba gal orf3b be protein feere je tuttama be lamba orf8.
The orf3b of SARS-CoV-2 may play a role in the viral pathogenicity and inhibit the expression of IFNβ; however, orf8 does not contain any known functional domain or motif.
orf3b SARS-CoV-2 footi naffa nder fuɗorde viriis e ɗon tuta ko mbiyotto IFNβ; ama, orf8 maray kuje je foooti huwa mala mandol.
On February 18, 2020, Zhou, et al., reported the cryo-EM structure of the full-length human ACE2 at 2.9 Å resolution in complex with the amino acid transporter B0AT1.
Ha 18 Feviriye 2020, Zhou, et al., wi'i yo'o tagol cryu-EM je darnde man footi be je neɗɗo ACE2 ha 2.9 A be hawtirde be rondowo BOAT1 neeɗam amino.
They found that the complex, which had open and closed conformations, was assembled as a dimer and the ACE2-B0AT1 complex can bind two S proteins, which provides evidence for CoV recognition and infection.
Ɓe tawi yo'o hawtirde ndu, je maɓɓiti e maɓɓi tagleji ngel, hawti bana laɓɓay e hawtirde ACE2-B0AT1 footi jokkita proteinji S didi, je don hokka sappinol ngam aandugo CoV be raɓɓol.
B0AT1 may become a therapeutic target for drug screening to suppress SARS-CoV-2 infection.
BOAT1 footi lata ko hurgol larni ngam lartol lekki ngam mbardugo nyau SARS-CoV-2.
The origin and intermediate host
Suudu ɗaaɗol be cakkare
It has been known that both SARS-CoV and MERS-CoV originated from bats and were transmitted to humans via civet cats and camels, respectively.
Ɓe aandini yo'o ɗiɗi fu SARS-CoV be MERS-CoV wurti ha bilwili e sallinama ha neɗɗo gal daabaji bana paturu paaɗawu be ngeeloba, feere.
Through a phylogenetic comparison of SARS-CoV-2 with other CoVs, bats were considered the native host of SARS-CoV-2 as the new virus is 96% identical to two SARS-like CoVs from bats called bat-SL-CoVZX45 and bat-SL-CoVZX21.
Gal fondugo tagol SARS-CoV-2 be CoV ji feere, bilwili woni bana arandere cuudi SARS-CoV-2 bana viriis keese lati 96% don nandi be irin SARS CoV ji je wurtungel ha bilwili je mbiyotto bilwili-SL-CoVZX45 be bilwili-SL-CoVZX21.
However, what intermediate host helped the virus cross the species barrier to infect humans remains unknown, and the transmission route is yet to be elucidated.
Ama, suudu toy on mballi viriis ngam sallugo mahdi feere ha raɓɓa neɗɗo aandake, e lawal je o hoosi bo'o sey goɗɗo teffa fahin tawon.
Ji, et al., proposed snakes as a carrier of the virus from bats to humans which involved homologous recombination within the S protein.
Ji et al., hoosi mboodi bana footi sallina nyau ndu diga bilwili ha neɗɗo je ɗon hawti kawtirol kalkal ha nder prootein. S
According to a study, researchers in Guangzhou, China, suggested that pangolins - long-snouted, ant-eating mammals often used in traditional Chinese medicine - are the potential intermediate host of SARS-CoV-2 based on 99% genetic homology in a CoV discovered in pangolins and SARS-CoV-2.
Ha sappinol ekkitol feere, teffoɓe ha Guanzhou, Cayna, tawi yo'o wodi daaba feere je mbiyotto pangolin je juttungel, je nyamatta hondorɗe, je lati bana lekki ha yimɓe Cayna feere, footi wona cakkare suudu SARS-CoV-2 ngam tagɗe maɓɓe ɗon naandi ha 99% be CoV je be tawi ha nder pangolin be SARS-CoV-2.
However, 1% difference spread all over two genomes is still a big difference; thus, conclusive results for concrete evidence are awaited (Fig. ​(Fig.33).
Ama, feeretirol 1% wondan hakkunde genomeji ɗiɓi footi wona feerotirol manga; nden kadi, en don reni sappinolji ekkitol ndu (Foto (Foto 33).
The physicochemical properties of SARS-CoV-2 are largely not yet known.
Hawtirde tagle SARS-CoV burna man aandaka tawon sam.
SARS-CoV and MERS-CoV can survive in vitro for 48 hours in a dry environment and up to 5 days under 20 °C and 40%-50% humidity.
SARS-CoV-2 be MERS-CoV footi yeeɗita to ɗon maɓɓi ha nder njamdi 48 ha do baabal je ɗon yoori e ha balde 5 nder guldum 20 °C be peewol 40% ha 50%.
SARS-CoV-2 may possess similar properties.
SARS-CoV-2 footi mara naandu be man.
It has been reported that SARS-CoV-2 is sensitive to ultraviolet rays and heat at 56 °C for 30 minutes; ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid, chloroform, and other fatty solvents, but not chlorhexidine, can effectively inactivate the virus.
Ɓe mbiy yo'o, SARS-CoV-2 ɗon hulla ultraviolet be gulɗum je ɓuri 56 °C nder minti 30; ether, 75% ethanol, kuje je mbarata gilɗi be chlorine, peracetic acid, chloroform, be kuje laybugo je ɗon mari ɓeleere, ama na chlorhexidine, footi mbarda viriis man be fakatre.
The entire human population generally lacks immunity to SARS-CoV-2 and hence is susceptible to the novel virus.
Ummatore yimɓe fu wala lekki ha SARS-CoV-2 e nden kadi lati bana ni be viriis je keese ndu bo'o.
Currently, no detailed study has been reported regarding the immunological response to SARS-CoV-2.
Jonta, wala ekkitol be ta'irde wangi ngam ko larni jabbuye ha do SARS-CoV-2.
Thus, we can only refer to previous studies on other CoVs, especially SARS-CoV and MERS-CoV (Fig. ​(Fig.4).4).
Nden kadi, sey en footi lartugo ekkitolji do CoV ji feere, ɓurna SARS-CoV be MERS-CoV (Foto (Foto 4).4).
In general, after a virus invades the host, it is first recognized by the host innate immune system through pattern recognition receptors (PRRs) including C-type lectin-like receptors, Toll-like receptor (TLR), NOD-like receptor (NLR), and RIG-I-like receptor (RLR).
Ɓurna fu, to viriis nasti ha ɓaandu, fadooɓe ɓaandu famman ɗum tawon gal joɓɓe maandol aandal (PRR) be jaɓɓoɓe irin lectin C, jabbowo irinToll (TLR), jaɓɓoɓe bana NOD (NLR), be jaɓɓowo irin RIG-I (RLR).
Through different pathways, the virus induces the expression of inflammatory factors, maturation of dendritic cells, and synthesis of type I interferons (IFNs) which limit the spreading of the virus and accelerate macrophage phagocytosis of viral antigens.
Gal laabi je feere-feere, viriis ɗon fuɗɗa sappinol ko footi ngaɗa nyau, ɓendugo cellji dendritic, cakkare irin interferonji I (IFNs) je ɗon haaɗa yajjugo viriisji e ɗon yaawina mbarol ɗajji viriis ndu.
However, the N protein of SARS-CoV can help the virus escape from the immune responses.
Amma, protein N SARS-CoV footi mballa viriis wurta jabbuji fadol ɓaandu.
Soon, the adaptive immune response joins the fight against the virus.
Seeɗa ni, jabbuye ngam fadugo ɓaandu fuɗɗan haɓɓugo be viriis.
T lymphocytes including CD4+ and CD8+ T cells play an important role in the defense.
Lymphociteji T be CD4+ be CD8+ T footi wona kandudum ha nder haɓre.
CD4+ T cells stimulate B cells to produce virus-specific antibodies, and CD8+ T cells directly kill virus-infected cells.
CD4+ cellji T umminan cellji B ngam suuftugo fadooɓe ɓaandu je haɓɓata be viriis, e CD8+ cellji T ha mbara cellji je viriis memmi timmi.
T helper cells produce proinflammatory cytokines to help the defending cells.
Mballowo ɓaandu T don illina cytokine je mballata bandu ngam habre.
However, CoV can inhibit T cell functions by inducing apoptosis of T cells.
Ama, CoV footi tutta kuɗe T cell gal nastinugo apostosis T cellji.
The humoral immunity including complements such as C3a and C5a and antibodies is also essential in combating the viral infection.
Fadol je ɓaandu wangini be kujeji bana C3a be C5a be ko ɓe ɗon waɗa habre ha nder iyam lati kandudum nder hurgol nyau viriis.
For example, antibodies isolated from a recovered patient neutralized MERS-CoV.
Bana sappinol, fadowo ɓaandu je jo'inama ha seera ha nyauɓo je nyambitti naatini no MERS-CoV.
On the other hand, an overreaction of the immune system generates a large number of free radicals locally that can cause severe damages to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.
Ha yakke feere, turtol kuje je fadata ɓaandu ɗon tutta wagare limgal ɗaaɗi ha wakere ndu je footi nawna fuffu kujeji feere, e to wala sa'a bo'o memman kujeji jur nder ɓaandu e footi wade tokka.